Drug Trial Radar · NCT07328971
Vancomycin Taper to Prevent Recurrent Clostridioides Difficile
Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
500
Planned (sponsor's estimate)
Start
May 1, 2026
Primary completion
Jul 1, 2031
Study completion Sep 1, 2031
Sponsor
- Lead sponsor
- McGill University Health Centre/Research Institute of the McGill University Health CentreAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jan 9, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Indirect evidence from network meta-analyses of randomized controlled trials (RCTs) suggest that a pulse and taper (P-T) of vancomycin may be non-inferior to 10-days of fidaxomicin for the prevention of recurrent Clostridioides difficile infections (rCDI). The aim of this trial is: 1\) For first episodes and first recurrences of CDI, to test whether a vancomycin P-T is non-inferior to 10-days of fidaxomicin for the prevention of rCDI at 56 days
Conditions
- Clostridia Difficile Colitis
Interventions
FidaxomicinDrug
Fidaxomicin 200mg PO BID x 10 days
Vancomycin capsuleDrug
Vancomycin 125mg PO QID x2 weeks, then 125mg PO BID x2 weeks, then 125mg PO daily x2 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- CDI RecurrenceTime frame: 56 days
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
University of Alberta
Edmonton, Alberta, Canada · Recruiting
McGill University Health Centre
Montreal, Quebec, Canada · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.